Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | LIPE | Q05469 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469375 | 0.81 | KEAP1 (0.47) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL1290949 | 0.80 | KDM4E (0.46) | KDM4EMEN1KMT2APOLBLIPE | |
| SCHEMBL12469040 | 0.80 | MEN1 (0.51) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL21628068 | 0.79 | HSPB1 (0.60) | MEN1KMT2ARAB9ALIPEALDH1A1 | |
| SCHEMBL13983607 | 0.78 | KDM4E (0.61) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL1478338 | 0.77 | CDK8 (0.46) | LIPE | |
| SCHEMBL6178262 | 0.77 | KDM4E (0.59) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL20931746 | 0.77 | KDM4E (0.79) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL15643189 | 0.75 | PARP10 (0.64) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL381901 | 0.75 | ALDH1A1 (0.52) | KDM4EMEN1KMT2APOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. | 2015-04-16 | — | — | US | disclosed |
| US-8946437-B2 | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2624833-B1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2624833-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046825-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, GLS2 | KDM4E 480/4885MEN1 617/4885KMT2A 126/4885 |
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, MDH2 | KDM4E 446/4885MEN1 639/4885KMT2A 141/4885 |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, MDH2, IDH2 | KDM4E 413/4885MEN1 616/4885KMT2A 108/4885 |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | KDM4E 488/4885MEN1 619/4885KMT2A 132/4885 |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | IDH2, MDH2, HCCS | KDM4E 404/4885MEN1 599/4885KMT2A 110/4885 |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | KDM4E 488/4885MEN1 619/4885KMT2A 132/4885 |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | KDM4E 488/4885MEN1 619/4885KMT2A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.